REINFORCED PROPHYLAXIS OF GVH IN ELDERLY PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: USE OF A LOW DOSE OF POST-ALLOGRAFT ANTI-LYMPHOCYTIC SERUM (CASPER)

Inclusion Criteria: Adults aged ≥ 60 or aged 50 to 59 with comorbidities (HCT-CI10 score ≥ 3), Hematological malignancies except myeloproliferative syndrome and myelodysplastic syndrome, Patient having received an allograft within ≤ 35 days, performed with the following modalities: First allogeneic transplant, Haploidentical donor, Peripheral stem cell transplant, Non-myeloablative "Baltimore"-type conditioning, delivered as standard in routine care, as reported in the literature (fludarabine, cyclophosphamide, total body irradiation), Standard GVHD prophylaxis in the context of haploidentical transplants (post-transplant cyclophosphamide, ciclosporin A and mycophenolate mofetil). Patient discharged from aplasia within ≤ 35 days, Signed informed consent form, Affiliation with a social security. Exclusion Criteria: Previous allogeneic or organ transplant, Presence of signs of GVHD, Contraindications to treatment with Thymoglobuline®, Hypersensitivity to rabbit proteins or to any of the excipients listed in the "Composition" section of the summary of product characteristics, Pregnant women or may become pregnant (without effective contraception) or breast-feeding, Persons in emergency situations or unable to give informed consent form, Adult with a legal protection measure (adult under guardianship, curatorship or safeguard of justice), Unable to comply with medical follow-up for geographical, social or psychological reasons.